Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
Public ClinicalTrials.gov record NCT02181738. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
Study identification
- NCT ID
- NCT02181738
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 294 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- Doxorubicin Drug
- Vinblastine Drug
- Dacarbazine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2014
- Primary completion
- Aug 30, 2017
- Completion
- Dec 26, 2022
- Last update posted
- Nov 27, 2023
2014 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0030 | Los Angeles | California | 90048 | — |
| Local Institution - 0009 | Los Angeles | California | 90095 | — |
| Local Institution - 0001 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0002 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0025 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0041 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0008 | Detroit | Michigan | 48201 | — |
| Local Institution - 0003 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0047 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0040 | Basking Ridge | New York | 07920 | — |
| Local Institution - 0005 | New York | New York | 10021 | — |
| Local Institution - 0006 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0004 | Nashville | Tennessee | 37232-6307 | — |
| Local Institution - 0007 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02181738, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 27, 2023 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02181738 live on ClinicalTrials.gov.